2 weeks Ago By Defense World Staff
A number of research firms have changed their ratings and price targets for Celldex Therapeutics (NASDAQ: CLDX): 9/30/2024 – Celldex Therapeutics is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $45.
00 price target on the stock. 9/27/2024 – Celldex Therapeutics was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating. 9/26/2024 – Celldex Therapeutics was upgraded by analysts at Wells Fargo & Company from a “hold” rating to a “strong-buy” rating.
9/26/2024 – Celldex Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
9/25/2024 – Celldex Therapeutics had its “outperform” rating reaffirmed by analysts at Wolfe Research. They now have a $51.00 price target on the stock.
9/16/2024 – Celldex Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
9/9/2024 – Celldex Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
8/12/2024 – Celldex Therapeutics had its price target raised by analysts at Wells Fargo & Company from $35.00 to $37.00.
They now have an “equal weight” rating on the stock. 8/12/2024 – Celldex Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $80.
00 price target on the stock. Celldex Therapeutics Trading Down 4.7 % Shares of NASDAQ:CLDX traded down $1.
59 during midday trading on Tuesday, reaching $32.40. The company had a trading volume of 992,550 shares, compared to its average volume of 857,051.
The company’s 50 day moving average price is $38.30 and its 200 day moving average price is $38.18.
The stock has a market cap of $2.15 billion, a P/E ratio of -11.37 and a beta of 1.
56. Celldex Therapeutics, Inc. has a 52-week low of $22.
11 and a 52-week high of $53.18. Celldex Therapeutics ( NASDAQ:CLDX – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th.
The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.
05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.
18%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.
13 million. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.
5 EPS for the current fiscal year. Institutional Trading of Celldex Therapeutics Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Recommended Stories Five stocks we like better than Celldex Therapeutics Buy P&G Now, Before It Sets A New All-Time High Why Lennar Stock Could Be the Best Play in the Housing Market Insider Trades May Not Tell You What You Think 2 Energy Stocks Fueling the AI Datacenter Boom Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? Receive News & Ratings for Celldex Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter ..
